Table 3.
Characteristics of included SARS-CoV studies (n = 2).
| Source | Country | Study design | Viral aetiology | Diagnosis | Sample | Reported co-morbidities | Symptoms on admission | Agea | Intervention | Non-intervention treatments |
|---|---|---|---|---|---|---|---|---|---|---|
| Zhao et al. (2003) | China | Randomized Clinical Trial |
SARS-CoV-1 | SARS clinical inclusion criteria | 190 | NI | Fever, Cough, Shortness of breath, Chest pain, Myalgia, Headache, Dizziness, Fatigue, Diarrhea, palpitation, Chills/Rigor | M(28.6) (group A:(33.6), group B:(32.4), group C:(32.5), group D: (30.5)), S(10.3) (group A: (13.9), group B:(12.4), group C:(12.1), group D: (12.3)), R(16–84) |
30 cases in group B: recombinant IFN-a, I.M. 3,000,000 U/day, Some cases in group C: IFN-a IM. 3,000,000 U/day), 45 cases in group D: IFN-a I.M. 3000000U/day | RBV, Methylprednisolone, Antibiotic |
| Loutfy et al. (2003) | Canada | Cohort | SARS-CoV-1 | Clinical inclusion criteria and IgG sample testing | 22 | HTN | NI | M (IFN Alfacon-1 group (−48), Corticosteroids Alone group (−42), R(IFN Alfacon-1 (27–56), Corticosteroids Alone (16–86)) |
IFN- alfacon-1 (9) | IVIG, Corticosteroids, High-dose methylprednisolone, Antibiotics, OF (Maximum steroid dose, mg (IFN Alfacon-1 group 500 (50–500) Corticosteroids Alone group 70 (40–500))) |
Abbreviations: CoV: coronavirus, IFN: interferon, igG: immunoglobulin G, IM: intramuscular, IVIG: intravenous immune globulin, M: mean, O: other formats, R: range, RBV: ribavirin, SARS: severe acute respiratory syndrome, U: unit.
a
Age of participants is reported as reported in each study. Estimated mean values may be found in (supplementary material).